Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Multivalent Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
39
States / cities
Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

NCT00000795
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Peptide Immunogen, Multivalent
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

NCT05004181
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions
BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
14
States / cities
Long Beach, California • San Diego, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 19, 2026, 2:32 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
20
States / cities
Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794
View directory record Official record
Conditions
Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37,864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

NCT06182124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC), Licensed pneumococcal comparator vaccine, Multivalent Pneumococcal Vaccine - Formulation 3, Multivalent Pneumococcal Vaccine - Formulation 4
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
20
States / cities
Doral, Florida • Hialeah, Florida • Stockbridge, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

NCT07660198
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Months to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 19, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

NCT07573462
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
23
States / cities
Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

NCT03765073
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 40 Years
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 19, 2026, 2:32 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

NCT06524414
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
61
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT02851277
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

NCT00579423
View directory record Official record
Conditions
Prostate, Cancer
Interventions
QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 19, 2026, 2:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 211 Days
Enrollment
3,230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
106
States / cities
Bessemer, Alabama • Birmingham, Alabama • Centreville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

NCT05968846
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

NCT05831124
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 19, 2026, 2:32 AM EDT